Thompson Siegel & Walmsley
ESPR icon

Thompson Siegel & Walmsley’s Esperion Therapeutics ESPR Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,400
Closed -$130K – 701
2015
Q1 		$130K Buy
+1,400
New +$90.3K ﹤0.01% 416

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Thompson Siegel & Walmsley's ESPR Position: Q2 2015 in Review

Thompson Siegel & Walmsley sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 1,400 shares — an estimated $130K sold.

Thompson Siegel & Walmsley first reported a position in ESPR in Q1 2015 and held it in 1 quarter. The position peaked at $130K in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

  • Thompson Siegel & Walmsley reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 1,400 Esperion Therapeutics shares in Q2 2015, an estimated $130K.
  • Thompson Siegel & Walmsley first reported a position in Esperion Therapeutics in Q1 2015 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Esperion Therapeutics position peaked at $130K in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2015, filed 3 Aug 2015.